EcoDrugPlus

Integrin Subunit Alpha V

Ensembl ID : ENSSCUG00000002378
Gene Symbol: ITGAV
3 Cross references
243 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 1

Ensembl ID : ENSSCUG00000007867
Gene Symbol: ITGB1
3 Cross references
299 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 3

Ensembl ID : ENSSCUG00000009297
Gene Symbol: ITGB3
3 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 6

Ensembl ID : ENSSCUG00000009870
Gene Symbol: ITGB6
3 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Integrin Subunit Beta 8

Ensembl ID : ENSSCUG00000010554
Gene Symbol: ITGB8
3 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSSCUG00000016152
Gene Symbol: IRAK4
3 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interleukin 6

Ensembl ID : ENSSCUG00000007012
Gene Symbol: IL6
3 Cross references
162 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Interleukin-8-Like

Ensembl ID : ENSSCUG00000017321
Gene Symbol: LOC104149934
2 Cross references
167 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSSCUG00000013175
Gene Symbol: IDH1
3 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSSCUG00000013168
Gene Symbol: IDH2
3 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinase Insert Domain Receptor

Ensembl ID : ENSSCUG00000001805
Gene Symbol: KDR
3 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kinesin Family Member 11

Ensembl ID : ENSSCUG00000016917
Gene Symbol: KIF11
3 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).